Company profile for T-knife

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

T-knife is set out to revolutionize the TCR landscape with its unique and proprietary transgenic HuTCR mouse platform to produce fully human TCRs. These TCRs mimic the properties of virus-specific TCRs avoiding immunological tolerance to self tumor antigens in humans. T-knife’s TCRs do not require additional modification but are naturally selected in vivo for an optimal affinity/specificity combination. The Company´s...
T-knife is set out to revolutionize the TCR landscape with its unique and proprietary transgenic HuTCR mouse platform to produce fully human TCRs. These TCRs mimic the properties of virus-specific TCRs avoiding immunological tolerance to self tumor antigens in humans. T-knife’s TCRs do not require additional modification but are naturally selected in vivo for an optimal affinity/specificity combination. The Company´s lead TCR has entered clinical development in an academic investigator-initiated study in patients with multiple myeloma.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Germany
Address
Address
Robert-Rössle-Str. 10 Berlin, Berlin 13125, DE
Telephone
Telephone
+49 30 94892432
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/17/3189058/0/en/T-knife-Therapeutics-Files-Clinical-Trial-Application-for-Phase-1-ATLAS-Trial-for-TK-6302-a-Supercharged-PRAME-targeted-T-Cell-Receptor-Therapy.html

GLOBENEWSWIRE
17 Nov 2025

https://www.globenewswire.com/news-release/2025/11/07/3183683/0/en/T-knife-Therapeutics-Presents-Preclinical-Data-on-PRAME-Targeted-TK-6302-Highlighting-its-Potential-as-a-Promising-Category-leading-Therapy-at-the-Society-for-Immunotherapy-of-Canc.html

GLOBENEWSWIRE
07 Nov 2025

https://www.globenewswire.com/news-release/2025/10/30/3177301/0/en/T-knife-Therapeutics-Announces-Four-Upcoming-Data-Presentations-on-PRAME-Targeted-TK-6302-at-the-Society-for-Immunotherapy-of-Cancer-SITC-Annual-Meeting.html

GLOBENEWSWIRE
30 Oct 2025

https://www.globenewswire.com/news-release/2025/10/07/3162553/0/en/T-knife-Therapeutics-Presents-Preclinical-Data-Highlighting-the-Transformative-Potential-of-the-MyT-Platform-to-Discover-and-Develop-Next-Generation-TCR-Therapies-to-Treat-Solid-Tu.html

GLOBENEWSWIRE
07 Oct 2025

https://www.globenewswire.com/news-release/2025/07/01/3108260/0/en/T-knife-Therapeutics-Appoints-Christoph-Broja-to-its-Board-of-Directors.html

GLOBENEWSWIRE
01 Jul 2025

https://www.globenewswire.com/news-release/2025/04/25/3068516/0/en/T-knife-Therapeutics-Presents-Preclinical-Data-at-the-American-Association-for-Cancer-Research-AACR-Annual-Meeting-Demonstrating-a-Potential-Best-in-Class-PRAME-Targeted-TCR-T-Ther.html

GLOBENEWSWIRE
25 Apr 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty